Odanwoma

Alchornea cordifolia contains polyphenols—including quercetin, gallic acid, ellagic acid, and rutin—alongside alkaloids such as alchorneine and yohimbine, which collectively drive antioxidant radical scavenging, anti-inflammatory enzyme inhibition, and antimicrobial membrane disruption. In rat models, a methanolic leaf extract at 50 mg/kg reduced carrageenan-induced paw oedema by 87.69%, and fruit aqueous extract inhibited Plasmodium falciparum (3D7 strain) with an IC50 of 4.9 µg/mL and a selectivity index exceeding 69.4.

Origin & History

Alchornea cordifolia is a shrub or small tree native to tropical and subtropical Africa, distributed widely across West, Central, and East Africa, including Ghana, Nigeria, Cameroon, and the Democratic Republic of Congo. It thrives in humid forest margins, riverbanks, savanna woodland edges, and disturbed secondary vegetation, tolerating a range of soil types at low to mid elevations. The plant is not formally cultivated commercially but is harvested from wild stands; leaves and fruits are gathered by traditional healers throughout the year, with leaves being the primary plant part used medicinally by the Akan people of Ghana.

Historical & Cultural Context

Among the Akan people of Ghana, Alchornea cordifolia—called Odanwoma—has been a cornerstone wound-healing and analgesic plant in traditional medicine for generations, with healers applying leaf decoctions directly to wounds and abscesses and administering oral preparations for fever, pain, and inflammatory conditions. Across West and Central Africa, the plant appears in ethnobotanical records under diverse local names in Yoruba, Igbo, and Hausa traditions in Nigeria, where it is used for malaria, sexually transmitted infections, rheumatism, and liver complaints, reflecting its broad pharmacological reputation. Traditional preparations typically involve pounding fresh leaves into poultices for topical application or boiling leaves and bark to produce decoctions consumed as teas, sometimes combined with other medicinal plants in composite formulations. The plant's prominence across multiple independent African ethnomedicinal systems—without cross-cultural diffusion as the primary driver—has been interpreted by ethnopharmacologists as corroborative evidence for genuine biological activity warranting systematic scientific investigation.

Health Benefits

- **Anti-Inflammatory Activity**: Methanolic leaf extract and isolated terpenoid/tannin fractions reduce experimental oedema by up to 87.69% in rat models, mediated by polyphenol-driven suppression of pro-inflammatory mediator production and oxidative cascade inhibition.
- **Wound Healing Support**: Traditional Akan use for topical wound management is supported by antimicrobial activity against skin-relevant pathogens and antioxidant capacity that may protect regenerating tissue from oxidative damage during healing.
- **Antimalarial Potential**: Aqueous fruit extract inhibits the chloroquine-sensitive P. falciparum 3D7 strain at an IC50 of 4.9 µg/mL with a selectivity index greater than 69.4, indicating meaningful antiparasitic selectivity in preclinical assays.
- **Hepatoprotective Effects**: Aqueous leaf extract administered at 200–800 mg/kg reduced isoniazid/rifampicin-induced elevations in serum ALT and AST by 40–45% in Wistar rats, suggesting protection against drug-induced oxidative hepatotoxicity via antioxidant polyphenol pathways.
- **Antioxidant Capacity**: Methanolic leaf extracts demonstrate DPPH radical scavenging activity of 500.38 mg TE/g and ABTS scavenging of 900.64 mg TE/g, driven by high total phenolic content of up to 213.12 mg GAE/g.
- **Antimicrobial Broad Spectrum**: Ethanol leaf extracts exhibit low minimum inhibitory concentrations against Escherichia coli (ATCC 28923) and Bacillus subtilis (ATCC 6051), with activity also demonstrated against poultry bacterial pathogens, supporting traditional use for infectious wound management.
- **Antidiabetic and Cytotoxic Activity**: Methanolic and infusion extracts inhibit relevant metabolic enzymes and show selective cytotoxicity against hepatocellular carcinoma cell lines in vitro, with GC-MS identification of 84 bioactive compounds in the methanolic extract underpinning these multi-target effects.

How It Works

Polyphenolic compounds—particularly quercetin, gallic acid, ellagic acid, and rutin—donate hydrogen atoms and electrons to neutralize DPPH and ABTS free radicals in a concentration-dependent manner, interrupting lipid peroxidation chain reactions and reducing cellular oxidative burden. The anti-inflammatory effect is attributed to tannin and terpenoid fractions that likely inhibit cyclooxygenase and lipoxygenase pathways, suppressing prostaglandin and leukotriene synthesis and thereby reducing vascular permeability and oedema formation. Alkaloids including alchorneine and triisopentenyl guanidine may interact with adrenergic and imidazoline receptor subtypes, which could partly explain antinociceptive and cardiovascular effects observed in ethnopharmacological contexts. Antimalarial activity of the fruit aqueous extract likely involves disruption of haemozoin crystallization or interference with the parasite's antioxidant defences, while antimicrobial activity is attributed to phenolic compounds destabilizing bacterial cell membranes and inhibiting key biosynthetic enzymes.

Scientific Research

The evidence base for Alchornea cordifolia consists entirely of in vitro assays and animal studies; no peer-reviewed randomized controlled trials in human subjects have been published as of the most recent literature review. Preclinical anti-inflammatory studies in rats demonstrated 87.69% oedema reduction with methanolic extract at 50 mg/kg, and hepatoprotective studies used Wistar rat models with quantified ALT/AST reductions of 40–45% at doses of 200–800 mg/kg aqueous extract. Antioxidant and cytotoxic properties have been characterized by DPPH/ABTS assays and GC-MS profiling identifying 84 compounds, with antimalarial IC50 values reported against P. falciparum 3D7, though no clinical translation of these findings has been accomplished. Overall, the evidence is preliminary and preclinical in nature; study sample sizes are not systematically reported, methodological standardization is inconsistent across publications, and human bioavailability, pharmacokinetics, and efficacy data are entirely absent.

Clinical Summary

No human clinical trials investigating Alchornea cordifolia for any indication have been identified in the available literature. All efficacy data derive from in vitro cell-based assays and uncontrolled animal experiments, with the strongest preclinical signals in anti-inflammatory, antimalarial, and hepatoprotective endpoints. Effect sizes reported in animal models—such as 87.69% oedema reduction and 40–45% transaminase normalization—are pharmacologically notable but cannot be extrapolated to human therapeutic doses or outcomes without clinical validation. Confidence in clinical benefit is therefore very low, and the compound should be regarded as a candidate for future Phase I/II investigation rather than an evidence-based therapeutic agent.

Nutritional Profile

Leaves contain high concentrations of polyphenols (total phenolics 120.38–213.12 mg GAE/g in dry extract), flavonoids (9.66–57.18 mg RE/g), condensed tannins (0.55–1.50 mg EC/g), and anthocyanins (up to 5.53 mg C3GE/g in mature leaves). Identified individual phytochemicals include quercetin, quercetin arabinoside, gallic acid, protocatechuic acid, ellagic acid, rutin, myricetin, vitexin, quercitrin, kaempferol, naringenin, shikimic acid, and stigmasterol. Alkaloids present include yohimbine, alchorneine, and triisopentenyl guanidine, which contribute to the plant's unique pharmacological profile beyond polyphenol activity. Fruits yield essential oils containing methyl salicylate (25.3%) and citronellol (21.4%); macro- and micronutrient profiling (proteins, minerals, vitamins) has not been comprehensively published, and bioavailability of key polyphenols from food or extract matrices has not been determined in human studies.

Preparation & Dosage

- **Leaf Decoction (Traditional)**: Dried or fresh leaves boiled in water and consumed orally or applied topically; volume and frequency not standardized but widely practiced by Akan healers for wound washing and internal fever/pain management.
- **Aqueous Extract (Research)**: 200–800 mg/kg used in rat hepatoprotective studies; no human equivalent dose established—these values are not directly translatable to human supplementation.
- **Methanolic Extract (Research)**: 50 mg/kg used for anti-inflammatory endpoints in rodents; total phenolic content standardized to 120–213 mg GAE/g in research preparations, but no commercial standardized product exists.
- **Fruit Aqueous Extract (Research)**: Used in antimalarial studies at concentrations achieving IC50 4.9 µg/mL in vitro; preparation involves maceration or boiling of dried fruits in distilled water.
- **Ethanol Leaf Extract (Research)**: Employed in antimicrobial MIC assays; ethanol concentration and extraction ratio vary by laboratory protocol.
- **Standardization Note**: No commercial dietary supplement with defined standardization to any specific marker compound (e.g., quercetin, alchorneine) is currently available; all dosing data are strictly experimental.

Synergy & Pairings

Alchornea cordifolia's polyphenol-rich profile may synergize with other flavonoid-containing botanicals such as Moringa oleifera or Camellia sinensis (green tea), where combined quercetin, kaempferol, and catechin loads could produce additive or supra-additive antioxidant and anti-inflammatory effects through complementary radical scavenging and NF-κB pathway modulation. The presence of methyl salicylate in fruit essential oils suggests potential additive analgesic interaction with other salicylate-containing herbs such as willow bark (Salix alba), though this combination also amplifies anticoagulant risk. Yohimbine-class alkaloids in the plant may interact pharmacodynamically with adrenergic-active compounds, a consideration when stacking with stimulant or cardiovascular-active ingredients.

Safety & Interactions

Acute oral toxicity studies in rodents report an LD50 of 1131.4 mg/kg for aqueous leaf extract, classifying it as relatively low acute toxicity under standard Lorke criteria, though these data do not establish human safety thresholds. No specific adverse effects have been systematically documented in available preclinical literature; aqueous extract administered alone did not significantly alter liver transaminase levels in experimental animals, suggesting a reasonable short-term hepatic safety margin at tested doses. A notable pharmacodynamic interaction has been observed: aqueous extract at 800 mg/kg significantly attenuated isoniazid/rifampicin-induced hepatotoxicity, suggesting potential for interaction with antitubercular drugs and, by extension, other hepatically metabolized medications that warrant caution. Cytotoxic activity identified against hepatocellular carcinoma cells in vitro raises theoretical concerns about effects on normal proliferating cells at high doses; pregnancy and lactation safety has not been evaluated, and use in these populations cannot be recommended without clinical data.